{"altmetric_id":2111090,"counts":{"readers":{"mendeley":24,"citeulike":1,"connotea":0},"blogs":{"unique_users_count":2,"unique_users":[53390,56412],"posts_count":2},"googleplus":{"unique_users_count":1,"unique_users":["Lymphoma Hub"],"posts_count":1},"total":{"posts_count":29},"twitter":{"unique_users_count":17,"unique_users":["aftimosp","fmedinacunha","sip2uak","ECMC_UK","oncologyTVfeed","chriscogbillmd","mtmdphd","drcarradice","healthorder","gottarun1000","StefanoLuminari","InOncology","ASCO","Lymphoma_Doc","lymphomahub","melmehdi","FrancescoTurtu1"],"posts_count":26}},"selected_quotes":["@ASCO: Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma. ORR of 100%, PFS of 3 - 5 years in relapsed dz","rituximab and Hodgkin lymphoma"],"citation":{"abstract":"Universal expression of CD20 by malignant cells in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) led us to evaluate rituximab (R) as a therapeutic option.","abstract_source":"pubmed","altmetric_jid":"4f6fa5e93cf058f610005a18","authors":["Ranjana H. Advani","Sandra J. Horning","Richard T. Hoppe","Sarah Daadi","John Allen","Yasodha Natkunam","Nancy L. Bartlett"],"doi":"10.1200\/jco.2013.53.2069","first_seen_on":"2014-02-10T21:35:49+00:00","handles":[],"isbns":[],"issns":["1527-7755","0732-183X"],"issue":"9","journal":"Journal of Clinical Oncology","last_mentioned_on":1477668651,"links":["http:\/\/jco.ascopubs.org\/lookup\/doi\/10.1200\/JCO.2013.53.2069","http:\/\/jco.ascopubs.org\/content\/early\/2014\/02\/10\/JCO.2013.53.2069.long","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24516013","http:\/\/jco.ascopubs.org\/content\/early\/2014\/02\/10\/JCO.2013.53.2069.abstract","http:\/\/jco.ascopubs.org\/content\/32\/9\/912.long","http:\/\/jco.ascopubs.org\/content\/32\/9\/912.abstract","http:\/\/jco.ascopubs.org\/content\/32\/9\/912.short?rss=1&ssource=mfr","http:\/\/jco.ascopubs.org\/content\/32\/9\/912.full"],"pdf_url":"http:\/\/jco.ascopubs.org\/content\/early\/2014\/02\/10\/JCO.2013.53.2069.full.pdf","pmid":"24516013","pubdate":"2014-02-10T00:00:00+00:00","publisher":"American Society of Clinical Oncology","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"subjects":["neoplasms"],"title":"Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte\u2013Predominant Hodgkin Lymphoma","type":"article","volume":"32","mendeley_url":"http:\/\/www.mendeley.com\/research\/mature-results-phase-ii-study-rituximab-therapy-nodular-lymphocytepredominant-hodgkin-lymphoma"},"altmetric_score":{"score":24.222,"score_history":{"1y":0.25,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":24.222},"context_for_score":{"all":{"total_number_of_other_articles":7607694,"mean":6.5509374902442,"rank":308438,"this_scored_higher_than_pct":95,"this_scored_higher_than":7299339,"rank_type":"exact","sample_size":7607694,"percentile":95},"similar_age_3m":{"total_number_of_other_articles":195217,"mean":7.2472641279406,"rank":9927,"this_scored_higher_than_pct":94,"this_scored_higher_than":185290,"rank_type":"exact","sample_size":195217,"percentile":94},"this_journal":{"total_number_of_other_articles":7974,"mean":13.128175843472,"rank":902,"this_scored_higher_than_pct":88,"this_scored_higher_than":7072,"rank_type":"exact","sample_size":7974,"percentile":88},"similar_age_this_journal_3m":{"total_number_of_other_articles":131,"mean":26.524876923077,"rank":35,"this_scored_higher_than_pct":73,"this_scored_higher_than":96,"rank_type":"exact","sample_size":131,"percentile":73}}},"demographics":{"poster_types":{"member_of_the_public":10,"researcher":1,"practitioner":4,"science_communicator":2},"users":{"twitter":{"cohorts":{"Members of the public":10,"Scientists":1,"Practitioners (doctors, other healthcare professionals)":4,"Science communicators (journalists, bloggers, editors)":2}},"mendeley":{"by_status":{"Unspecified":1,"Professor > Associate Professor":1,"Researcher":10,"Student  > Doctoral Student":3,"Student  > Postgraduate":1,"Other":3,"Student  > Master":1,"Student  > Bachelor":2,"Lecturer":1,"Professor":1},"by_discipline":{"Medicine and Dentistry":19,"Agricultural and Biological Sciences":2,"Mathematics":1,"Unspecified":1,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"twitter":{"BR":1,"ID":1,"GB":2,"US":6,"AU":1,"IN":1,"MA":1,"BE":1}}},"posts":{"googleplus":[{"title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin l...","url":"https:\/\/plus.google.com\/104484290654217117636\/posts\/4DovwUTzUwN","citation_ids":[2111090],"posted_on":"2014-02-14T01:55:20+00:00","summary":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin l... Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.http:\/\/ow.ly\/tAAM7\ufeff Mature Results of a Phas","author":{"name":"Lymphoma Hub","url":"https:\/\/plus.google.com\/+Lymphomahub","image":"https:\/\/lh4.googleusercontent.com\/-SlgPP69chxQ\/AAAAAAAAAAI\/AAAAAAAAAO4\/atxbhhEd5FM\/photo.jpg?sz=50","id_on_source":"104484290654217117636"}}],"twitter":[{"url":"http:\/\/twitter.com\/fmedinacunha\/status\/447881437094477824","license":"datasift","citation_ids":[2111090],"posted_on":"2014-03-23T23:43:50+00:00","author":{"name":"Fernando Medina","url":"http:\/\/www.oncologia.com.br","image":"https:\/\/pbs.twimg.com\/profile_images\/869486813358022656\/oJ_lULIb_normal.jpg","description":"Oncologista, doutor em medicina pela Universidade de Campinas e Free university,  Amsterdan,  Holanda.","id_on_source":"fmedinacunha","tweeter_id":"53357369","geo":{"lt":-22.90556,"ln":-47.06083,"country":"BR"},"followers":182},"tweet_id":"447881437094477824"},{"url":"http:\/\/twitter.com\/sip2uak\/status\/448847699048431617","license":"public","rt":["ASCO"],"citation_ids":[2111090],"posted_on":"2014-03-26T15:43:25+00:00","author":{"name":"Syifa'u Warahmah","url":"http:\/\/sip2uak.blogspot.com","image":"https:\/\/pbs.twimg.com\/profile_images\/716958377880920064\/P0-wbzT__normal.jpg","description":"| gag mau ikut campur urusan org (titik) | AB(+) | epidemiologist | barcelonanista | urang awak |","id_on_source":"sip2uak","tweeter_id":"72813618","geo":{"lt":-0.94924,"ln":100.35427,"country":"ID"},"followers":209},"tweet_id":"448847699048431617"},{"url":"http:\/\/twitter.com\/ECMC_UK\/status\/448850104364335104","license":"public","rt":["ASCO"],"citation_ids":[2111090],"posted_on":"2014-03-26T15:52:58+00:00","author":{"name":"ECMC Network","url":"http:\/\/www.ecmcnetwork.org.uk\/","image":"https:\/\/pbs.twimg.com\/profile_images\/862293791776153600\/cE1gcFvg_normal.jpg","description":"Experimental Cancer Medicine Centres drive development of new cancer therapies. Jointly funded @CR_UK & @OfficialNIHR @CSO_Scotland @ResearchWales @BelfastTrust","id_on_source":"ECMC_UK","tweeter_id":"1903979808","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":1760},"tweet_id":"448850104364335104"},{"url":"http:\/\/twitter.com\/oncologyTVfeed\/status\/449247836899930112","license":"public","rt":["ASCO"],"citation_ids":[2111090],"posted_on":"2014-03-27T18:13:25+00:00","author":{"name":"Oncology.TV","url":"http:\/\/www.oncology.tv","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000762635706\/88b1780b8f61c4021ab22913a6507886_normal.jpeg","description":"Free #oncology CE and non CE programs on the latest clinical information to #physicians, #nurses and #healthcare professionals. #MedED","id_on_source":"oncologyTVfeed","tweeter_id":"331866943","geo":{"lt":null,"ln":null},"followers":359},"tweet_id":"449247836899930112"},{"url":"http:\/\/twitter.com\/chriscogbillmd\/status\/449011452297621504","license":"public","rt":["ASCO"],"citation_ids":[2111090],"posted_on":"2014-03-27T02:34:07+00:00","author":{"name":"Chris Cogbill, MD","image":"https:\/\/pbs.twimg.com\/profile_images\/812517512541716480\/w6fd9d4J_normal.jpg","description":"Pathologist in WI | Interests: #hemepath #Lymphoma #leukemia #pathology #hematology #surgpath | @ASCP_Chicago Volunteer","id_on_source":"chriscogbillmd","tweeter_id":"7334512","geo":{"lt":43.80136,"ln":-91.23958,"country":"US"},"followers":1401},"tweet_id":"449011452297621504"},{"url":"http:\/\/twitter.com\/mtmdphd\/status\/478993376441028608","license":"datasift","citation_ids":[2111090],"posted_on":"2014-06-17T20:11:34+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15377},"tweet_id":"478993376441028608"},{"url":"http:\/\/twitter.com\/drcarradice\/status\/434527700292603904","license":"public","rt":["lymphomahub"],"citation_ids":[2111090],"posted_on":"2014-02-15T03:20:51+00:00","author":{"name":"Dr Duncan Carradice","url":"http:\/\/www.duncancarradice.com.au","image":"http:\/\/pbs.twimg.com\/profile_images\/1518901821\/Stethescope_normal.jpg","description":"A lymphoma and myeloma doc working in Western metropolitan Melbourne, Australia","id_on_source":"drcarradice","tweeter_id":"285483180","geo":{"lt":"-37.8142176","ln":"144.9631608","country":"AU"},"followers":23},"tweet_id":"434527700292603904"},{"url":"http:\/\/twitter.com\/healthorder\/status\/448921046792830976","license":"public","rt":["mtmdphd"],"citation_ids":[2111090],"posted_on":"2014-03-26T20:34:52+00:00","author":{"name":"Gilda","url":"http:\/\/amzn.to\/1cPj47o","image":"http:\/\/pbs.twimg.com\/profile_images\/378800000839663405\/c3d139df0f653b7564958b2afd407b46_normal.jpeg","description":"Health Personal Care http:\/\/amzn.to\/1cPj47o Baby Child #HealthCare House Medical Supplies Equipment Wellness Sports Nutrition Vitamins Dietary Supplements","id_on_source":"healthorder","tweeter_id":"2220906834","geo":{"lt":"39.7837304","ln":"-100.4458825","country":"US"},"followers":507},"tweet_id":"448921046792830976"},{"url":"https:\/\/twitter.com\/mtmdphd\/status\/448920654809956352","license":"public","citation_ids":[2111090],"posted_on":"2014-03-26T20:33:19+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15377},"tweet_id":"448920654809956352"},{"url":"http:\/\/twitter.com\/gottarun1000\/status\/452523383708983296","license":"datasift","citation_ids":[2111090],"posted_on":"2014-04-05T19:09:16+00:00","author":{"name":"Scott Werntz","url":"http:\/\/www.miraclemiles.me","image":"http:\/\/pbs.twimg.com\/profile_images\/3322174087\/7bcb548396c7d0d27f93007cd3900f58_normal.jpeg","description":"I am running 1000 miles in 1 year in honor of David Hatfield to raise $100,000 for Lymphoma and Leukemia Society. Tune in regularly for breaking news!","id_on_source":"gottarun1000","tweeter_id":"1217238458","followers":95},"tweet_id":"452523383708983296"},{"url":"http:\/\/twitter.com\/StefanoLuminari\/status\/434331598843314176","license":"datasift","rt":["lymphomahub"],"citation_ids":[2111090],"posted_on":"2014-02-14T14:21:37+00:00","author":{"name":"Stefano Luminari, MD","image":"https:\/\/pbs.twimg.com\/profile_images\/541298140091924480\/IpEHk60K_normal.jpeg","description":"Medical oncologist\/hematologist involved in the treatment and clinical research programs of malignant lymphomas @unimore.it @asmn.re.it in Reggio Emilia, Italy","id_on_source":"StefanoLuminari","tweeter_id":"2192655026","geo":{"lt":null,"ln":null},"followers":274},"tweet_id":"434331598843314176"},{"url":"http:\/\/twitter.com\/InOncology\/status\/452587923129372672","license":"datasift","citation_ids":[2111090],"posted_on":"2014-04-05T23:25:44+00:00","author":{"name":"India Oncology 2.0","url":"https:\/\/www.facebook.com\/pages\/InOncology\/149384831739338","image":"https:\/\/pbs.twimg.com\/profile_images\/1075687841\/12_normal.png","description":"The Latest in Oncology","id_on_source":"InOncology","tweeter_id":"166079744","geo":{"lt":20,"ln":77,"country":"IN"},"followers":138},"tweet_id":"452587923129372672"},{"url":"http:\/\/twitter.com\/mtmdphd\/status\/479274715240882176","license":"datasift","citation_ids":[2111090],"posted_on":"2014-06-18T14:49:31+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15377},"tweet_id":"479274715240882176"},{"url":"http:\/\/twitter.com\/ASCO\/status\/448843405402329088","license":"public","citation_ids":[2111090],"posted_on":"2014-03-26T15:26:21+00:00","author":{"name":"ASCO","url":"http:\/\/www.asco.org","image":"https:\/\/pbs.twimg.com\/profile_images\/463779450388090880\/UsaXUpTx_normal.png","description":"ASCO is the American Society of Clinical Oncology. Making a world of difference in cancer care.","id_on_source":"ASCO","tweeter_id":"20187065","geo":{"lt":38.80484,"ln":-77.04692,"country":"US"},"followers":68966},"tweet_id":"448843405402329088"},{"url":"http:\/\/twitter.com\/Lymphoma_Doc\/status\/433675981031620608","license":"public","citation_ids":[2111090],"posted_on":"2014-02-12T18:56:25+00:00","author":{"name":"Jason Westin, MD","url":"http:\/\/faculty.mdanderson.org\/Jason_Westin\/Default.asp","image":"https:\/\/pbs.twimg.com\/profile_images\/910134436230025216\/KEOAxbnf_normal.jpg","description":"Lymphoma Specialist at MD Anderson Cancer Center, dreamer and doer, averse to status quo. Opinions are mine.","id_on_source":"Lymphoma_Doc","tweeter_id":"1080058020","geo":{"lt":29.76328,"ln":-95.36327,"country":"US"},"followers":3351},"tweet_id":"433675981031620608"},{"url":"http:\/\/twitter.com\/lymphomahub\/status\/434143785367658497","license":"public","citation_ids":[2111090],"posted_on":"2014-02-14T01:55:19+00:00","author":{"name":"Lymphoma Hub","url":"http:\/\/www.lymphomahub.com","image":"https:\/\/pbs.twimg.com\/profile_images\/816644675025207296\/mwybWyru_normal.jpg","description":"The LH is an online resource dedicated to sharing lymphoma\/CLL latest medical information  within the community hematologists, oncologists and hem-oncologists","id_on_source":"lymphomahub","tweeter_id":"1582593798","geo":{"lt":54.75844,"ln":-2.69531,"country":"GB"},"followers":1895},"tweet_id":"434143785367658497"},{"url":"http:\/\/twitter.com\/melmehdi\/status\/437331212651462656","license":"public","rt":["aftimosp"],"citation_ids":[2111090],"posted_on":"2014-02-22T21:01:00+00:00","author":{"name":"M. El Mehdi","url":"http:\/\/www.bloodlover.com","image":"https:\/\/pbs.twimg.com\/profile_images\/548811091074367488\/EjiEFdlA_normal.jpeg","description":"Moroccan hematologist since 2013. I save lives, sometimes. Tweets about life, music, art (lol) and hematology. Instagram: bloodlover84 Blood Type: No Negative","id_on_source":"melmehdi","tweeter_id":"59222986","geo":{"lt":34.01325,"ln":-6.83255,"country":"MA"},"followers":654},"tweet_id":"437331212651462656"},{"url":"http:\/\/twitter.com\/FrancescoTurtu1\/status\/445542689828642817","license":"public","citation_ids":[2111090],"posted_on":"2014-03-17T12:50:29+00:00","author":{"name":"Francesco Turturro","url":"http:\/\/faculty.mdanderson.org\/Francesco_Turturro\/Default.asp?SNID=1484660469","image":"https:\/\/pbs.twimg.com\/profile_images\/763530448618217472\/8el8ozjZ_normal.jpg","description":"Lymphoma specialist expressing his own opinions","id_on_source":"FrancescoTurtu1","tweeter_id":"1191609930","geo":{"lt":29.76328,"ln":-95.36327,"country":"US"},"followers":968},"tweet_id":"445542689828642817"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/684815483468689409","license":"gnip","citation_ids":[2111090],"posted_on":"2016-01-06T19:15:09+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15377},"tweet_id":"684815483468689409"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/730499044758290432","license":"gnip","citation_ids":[2111090],"posted_on":"2016-05-11T20:45:18+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15377},"tweet_id":"730499044758290432"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/741336805396602880","license":"gnip","citation_ids":[2111090],"posted_on":"2016-06-10T18:30:42+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15377},"tweet_id":"741336805396602880"},{"url":"http:\/\/twitter.com\/mtmdphd\/statuses\/792025844856258560","license":"gnip","citation_ids":[2111090],"posted_on":"2016-10-28T15:30:51+00:00","author":{"name":"Mike Thompson, MDPhD","url":"http:\/\/www.linkedin.com\/in\/michaelthompsonmdphd","image":"https:\/\/pbs.twimg.com\/profile_images\/2638189364\/9a817b84e5879a81121e476303368366_normal.png","description":"Heme\/Onc Researcher. @Aurora_Cancer Member: @ASCO @ASH_Hematology @Doximity. #mmsm, #lymsm, #ImmunoOnc, #ClinicalTrials Views=own","id_on_source":"mtmdphd","tweeter_id":"190337035","geo":{"lt":43.0389,"ln":-87.90647,"country":"US"},"followers":15377},"tweet_id":"792025844856258560"},{"url":"http:\/\/twitter.com\/FrancescoTurtu1\/status\/433223580206116865","license":"public","citation_ids":[2111090],"posted_on":"2014-02-11T12:58:45+00:00","author":{"name":"Francesco Turturro","url":"http:\/\/faculty.mdanderson.org\/Francesco_Turturro\/Default.asp?SNID=1484660469","image":"https:\/\/pbs.twimg.com\/profile_images\/763530448618217472\/8el8ozjZ_normal.jpg","description":"Lymphoma specialist expressing his own opinions","id_on_source":"FrancescoTurtu1","tweeter_id":"1191609930","geo":{"lt":29.76328,"ln":-95.36327,"country":"US"},"followers":968},"tweet_id":"433223580206116865"},{"url":"http:\/\/twitter.com\/lymphomahub\/status\/433273056803717121","license":"public","rt":["FrancescoTurtu1"],"citation_ids":[2111090],"posted_on":"2014-02-11T16:15:21+00:00","author":{"name":"Lymphoma Hub","url":"http:\/\/www.lymphomahub.com","image":"https:\/\/pbs.twimg.com\/profile_images\/816644675025207296\/mwybWyru_normal.jpg","description":"The LH is an online resource dedicated to sharing lymphoma\/CLL latest medical information  within the community hematologists, oncologists and hem-oncologists","id_on_source":"lymphomahub","tweeter_id":"1582593798","geo":{"lt":54.75844,"ln":-2.69531,"country":"GB"},"followers":1895},"tweet_id":"433273056803717121"},{"url":"http:\/\/twitter.com\/drcarradice\/status\/433715833416581120","license":"public","rt":["lymphomahub","FrancescoTurtu1"],"citation_ids":[2111090],"posted_on":"2014-02-12T21:34:47+00:00","author":{"name":"Dr Duncan Carradice","url":"http:\/\/www.duncancarradice.com.au","image":"http:\/\/pbs.twimg.com\/profile_images\/1518901821\/Stethescope_normal.jpg","description":"A lymphoma and myeloma doc working in Western metropolitan Melbourne, Australia","id_on_source":"drcarradice","tweeter_id":"285483180","geo":{"lt":"-37.8142176","ln":"144.9631608","country":"AU"},"followers":23},"tweet_id":"433715833416581120"},{"url":"http:\/\/twitter.com\/aftimosp\/status\/437330772761280512","license":"public","citation_ids":[2111090],"posted_on":"2014-02-22T20:59:16+00:00","author":{"name":"Philippe Aftimos, MD","url":"http:\/\/be.linkedin.com\/pub\/philippe-aftimos-md\/25\/a76\/664","image":"https:\/\/pbs.twimg.com\/profile_images\/832483544064602112\/cfYg9YGh_normal.jpg","description":"Medical Oncologist and senior research physician at @JulesBordet #Brussels. Developmental therapeutics, #BreastCancer #PrecisionMedicine. Views are my own.","id_on_source":"aftimosp","tweeter_id":"177176270","geo":{"lt":50.85045,"ln":4.34878,"country":"BE"},"followers":2420},"tweet_id":"437330772761280512"}],"blogs":[{"title":"Is Early Initiation of Adjuvant Chemotherapy for Breast Cancer Better?","url":"http:\/\/jco.ascopubs.org\/site\/podcasts\/index.xhtml","license":"public","citation_ids":[2160924,2129138,2077136,2111090,2111091],"posted_on":"2014-02-10T19:22:00+00:00","summary":"Early commencement of adjuvant chemotherapy is unlikely to be relevant for the majority of patients but unnecessary delay may be unwise for patients in whom the effect of adjuvant chemotherapy is expected to be significant.","author":{"name":"Journal of Clinical Oncology Podcast","url":"http:\/\/jco.ascopubs.org","description":"The Journal of Clinical Oncology (JCO) serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. Usually presented in conjunction with an original report and an editorial published on www.jco.org, the JCO podcasts enable readers to stay current on the latest research while placing the results into a clinically useful context."}},{"title":"Is Early Initiation of Adjuvant Chemotherapy for Breast Cancer Better?","url":"http:\/\/traffic.libsyn.com\/jcopodcast\/jcopodcast-02-10-2014-3.mp3","license":"public","citation_ids":[2160924,2129138,2077136,2111090,2111091],"posted_on":"2014-02-10T19:22:00+00:00","summary":"Early commencement of adjuvant chemotherapy is unlikely to be relevant for the majority of patients but unnecessary delay may be unwise for patients in whom the effect of adjuvant chemotherapy is expected to be significant.","author":{"name":"Journal of Clinical Oncology Podcast","url":"http:\/\/jco.ascopubs.org\/","description":"The Journal of Clinical Oncology (JCO) serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. Usually presented in conjunction with an original report and an editorial published on www.jco.org, the JCO podcasts enable readers to stay current on the latest research while placing the results into a clinically useful context."}}]}}